Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

PHASE1RecruitingINTERVENTIONAL

Enrollment

144

Participants

Timeline

Start Date

September 20, 2022

Primary Completion Date

May 31, 2025

Study Completion Date

July 31, 2027

Conditions

Advanced Non-Small Cell Lung Cancer

Interventions

DRUG

IBI351

recommended dose, po

DRUG

Cetuximab

500mg/m\^2, Q2W, day1, i.v.

DRUG

pemetrexed

500mg/m\^2, Q3W, day1, i.v.

DRUG

Carboplatin

AUC=5, Q3W, day1, i.v.

DRUG

Sintilimab

200mg, Q3W, day1, i.v.

DRUG

cis-platinum

75mg/m\^2, Q3W, day1, i.v.

Trial Locations (1)

RECRUITING

Jilin Province Cancer Hospital, Jilin

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY